

## LIST OF CONTENTS

Chapter	Page
<b>I INTRODUCTION</b> .....	1
Rationale for the study .....	1
Propose of the study.....	3
Significance of the study.....	6
Scope of the study.....	6
<b>II LITERATURE REVIEW</b> .....	7
Capsinoids.....	7
Biosynthesis .....	8
Stability of Capsinoids.....	9
Toxicity of Capsinoids.....	16
Biological Activities of Capsiate .....	17
Modification of Capsiate.....	22
<b>III RESEARCH METHODOLOGY</b> .....	24
Overview synthesis of capsinoid analogues (4-7) .....	24
Synthesis of ( <i>E</i> )-7-methyl-5-octenol (12-13) .....	24
Synthesis of capsinoid analogue 4 and 5 .....	25
Synthesis of mixture lipophilic chain carbon, ( <i>E</i> )-8-methyl- 6- nonenol (17) and 8-methylnonanol (18).....	25
Synthesis of capsinoid analogue 6 and 7 .....	26
Stability of capsinoid analogues (4-7) in polar protic solvent .....	26
Investigation of Cell Viability on Caco-2 cell <i>via</i> cytotoxicity MTT assays .....	26

## LIST OF CONTENTS (CONT.)

Chapter	Page
General procedure .....	27
Equipment .....	27
Materials .....	28
Synthesis of capsinoid analogues (4-7).....	29
Synthesis of capsinoid analogue 4 and 5 .....	29
Synthesis of capsinoid analogue 4 and 5 .....	32
Synthesis of capsinoid analogue 6 and 7 .....	33
Stability of capsinoid analogues (4-7) in polar protic solvent .....	36
Investigation of Cell Viability on Caco-2 cell <i>via</i> cytotoxicity	
MTT assays.....	36
<b>IV RESULTS AND DISCUSSION .....</b>	<b>39</b>
Synthesis of capsinoid analogue 4 and 5 .....	40
Synthesis of ( <i>E/Z</i> )-7-methyl-5-octenol (12 and 13).....	42
Synthesis of capsinoid analogue 4 and 5 .....	48
Synthesis of ( <i>E</i> )-8-methyl-6-nonenol (17) and 8-methylnonanol (18).....	51
Synthesis the mixture of capsinoid analogue 6 and 7.....	53
Stability of capsinoid analogues (4-7) in polar protic solvent .....	56
Investigation of Cell Viability on Caco-2 cell <i>via</i> cytotoxicity	
MTT assays .....	60
<b>V CONCLUSION.....</b>	<b>65</b>

## LIST OF CONTENTS (CONT.)

Chapter	Page
REFERENCES.....	66
APPENDIX.....	72
BIOGRAPHY.....	89

## LIST OF TABLES

Table	Page
1	Chemical structure of capsinoids ..... 1
2	Structures of capsiate (1), vanillyl nonanoate, six vanillyl nonanoate analogues and decomposition products, methyl vanillyl ether and ethyl vanillyl ether ..... 10
3	The substituted benzyl ester derivatives having a branched fatty acid side chain of capsinoids ..... 14
4	Characteristics of Subjects in the CH-19 Sweet (n = 7) and Control (n = 5) Groups When Measurements of Body Fat by BODPOD and CT Scan Were Carried Out during the Adjustment Period for Each Amount of Food Ingested and after 2 Weeks of Treatment ..... 20
5	Percent remaining of capsinoids analogues (4-7) compared with <i>E/Z</i> -capsiate (1) ..... 58
6	Calculated percent remaining of capsinoid analogue (4) ..... 85
7	Calculated percent remaining of capsinoid analogue (5) ..... 85
8	Calculated percent remaining of capsinoid analogue (6) ..... 86
9	Calculated percent remaining of capsinoid analogue (7) ..... 86
10	Calculated percent remaining of <i>E</i> -capsiate ..... 87
11	Calculated percent remaining of <i>Z</i> -capsiate ..... 87
12	%Cell viability of Caco-2 cell via cytotoxicity MTT assay at 18 hours ..... 88
13	%Cell viability of Caco-2 cell via cytotoxicity MTT assay at 24 hours ..... 88

## LIST OF FIGURES

Figure	Page
1	Structure comparison between capsaicinoids and capsinoids dividing into 3 parts; aromatic region (A-region), bond linkage region (B-region) and a lipophilic carbon chain (C-region) ..... 2
2	Degradation of capsinoids <i>via p</i> -quinone methide pathways..... 3
3	Conceptual modification of capsinoid analogues ..... 4
4	Proposed decomposition mechanism of capsinoid analogue through <i>p</i> -quinonemethide to compared with capsiate..... 4
5	Comparison of Resiniferatoxin (RTX) and capsinoid analogues on aromatic region and ester linkage ..... 5
6	Structure of capsinoid analogues (4-7) ..... 6
7	Structures of capsinoids ..... 7
8	Change in vanillyl nonanoate with time in various solvents (A) and several solvents containing water (B) at 25 °C ..... 11
9	Change in vanillyl nonanoate analogues with time in methanol at 25 °C : (●) vanillyl nonanoate; (▲) 4-acetoxy-3-methoxybenzyl nonanoate; (Δ) 3,4-dimethoxybenzyl nonanoate; (◇) 3-methoxybenzyl nonanoate; (□) <i>p</i> -hydroxybenzyl nonanoate; (○) <i>m</i> -hydroxybenzyl nonanoate; (◆) <i>o</i> -hydroxybenzyl nonanoate..... 13
10	A: the storage stability of dihydrocapsiate in a medium containing decaglycerin monooleate (DECAGLYNL 1-O) B: the storage stability of dihydrocapsiate in a media containing 8 types of emulsifiers..... 15
11	The storage stability of dihydrocapsiate when a capsinoid-containing added a polyglycerin fatty acid ester emulsifier in advance was diluted with an aqueous buffer containing no emulsifier..... 16

## LIST OF FIGURES (CONT.)

Figure	Page
12	The theoretical model of capsinoids and capsaicinoids activate anti-obesity..... 19
13	Time-Course Characteristics of Body Weight in the CH-19 Sweet (n = 7) and Control (n = 5) Groups.....20
14	Changes in Body Fat Percentage (A), Fat Mass (B) and Fat-Free Mass (C) Expressed as Relative Values during the Two-Week Treatment Period.....21
15	Changes in Total Fat Area (A), Visceral Fat Area (B) and Subcutaneous Fat Area (C) Expressed as Relative Values for the Two-Week Treatment Period.....22
16	cytotoxicity MTT assays procedure.....27
17	<sup>1</sup> H NMR Spectrum of (4-carboxybutyl)triphenylphosphonium bromide (9) δ 7.94-7.76 ppm verified aromatic protons of triphenyl group (m, aromatic-H, 15H) (D <sub>2</sub> O)..... 43
18	<sup>1</sup> H NMR Spectrum of (Z)-7-methyl-5-octenoic acid (10) identity signal of unsaturated protons at δ 5.29 – 5.12 ppm (m, CH=CH, 2H) (CDCl <sub>3</sub> ) ..... 41
19	<sup>1</sup> H NMR Spectrum of mixture (E/Z) -7-methyl-5-octenoic acid (11, 10) verified by signal of proton on tertiary carbon δ 2.27-2.18 ppm (m, CH, 1H) (CDCl <sub>3</sub> )..... 45
20	<sup>1</sup> H NMR Spectrum of mixture (E/Z)- 7-methyl-5-octenol (12 and 13) confirmed signal of proton on CH <sub>2</sub> carbon closely to OH group at δ 3.64 ppm (t, J=6.6 Hz, 2H) (CDCl <sub>3</sub> )..... 46
21	Overlay spectrum of mixture (E/Z)- 7-methyl-5-octenol (12 and 13) confirmed signal of proton on CH <sub>2</sub> carbon closely to OH group at δ 3.64 ppm (t, J=6.6 Hz, 2H) (CDCl <sub>3</sub> )..... 47

## LIST OF FIGURES (CONT.)

Figure	Page
22	Overlay FT-IR spectrum of mixture ( <i>E/Z</i> )-7-methyl-5-octenoic acid (11 and 10) and ( <i>E/Z</i> )-7-Methyl-5-octenol (12 and 13): 3,361 cm <sup>-1</sup> (O-H stretching), by missing of 1,658 cm <sup>-1</sup> (C=O stretching)..... 48
23	<sup>1</sup> H NMR Spectrum of capsinoid analogue 4 (CDCl <sub>3</sub> )..... 49
24	Overlay spectrum of homovanillic acid (14), ( <i>E/Z</i> )- 7-methyl-5-octenol (12 and 13) and capsinoid analogue 4 and 5 (CDCl <sub>3</sub> ) ..... 50
25	FT-IR spectrum of mixture capsinoid analogue 4 and 5: 3,447 cm <sup>-1</sup> of phenol (O-H stretching), 1,735 cm <sup>-1</sup> (C=O stretching), and 1,035 cm <sup>-1</sup> C-O stretching of ester bond..... 50
26	<sup>13</sup> C-NMR, DEPT 90 and DEPT 135 of capsinoid analogue 4 (400 MHz, CDCl <sub>3</sub> )..... 51
27	Overlay spectrum the mixture of ( <i>E</i> )-8-methyl-6-nonenol (17) and 8- methylnonanol (18) confirmed signal of proton on CH <sub>2</sub> carbon closely to OH group at δ 3.68 ppm (t, <i>J</i> =6.8 Hz, 4H) (CDCl <sub>3</sub> ) ..... 52
28	Overlay FT-IR spectrum of mixture ( <i>E</i> )-8-methyl-6-nonenol (17) and 8- methylnonanol (18) : 3,369 cm <sup>-1</sup> (O-H stretching), by missing of 1,710 cm <sup>-1</sup> (C=O stretching) ..... 53
29	<sup>1</sup> H NMR Spectrum of capsinoid analogue 6 and 7 (CDCl <sub>3</sub> )..... 54
30	Overlay spectrum of Homovanillic acid (14), ( <i>E</i> )-8-methyl-6-nonenol (17) and 8-methylnonanol (18) and capsinoid analogue 6 and 7 (CDCl <sub>3</sub> ) ..... 55
31	FT-IR spectrum of mixture capsinoid analogue 6 and 7: 3,446 cm <sup>-1</sup> of phenol (O-H stretching), 1,734 cm <sup>-1</sup> (C=O stretching), and 1,033 cm <sup>-1</sup> C-O stretching of ester bond..... 55
32	Chromatogram of capsinoid analogues (4-7) at 0 hour, C18, 4.6 x 250 mm, 5 μm, mobile phase, CH <sub>3</sub> OH:H <sub>2</sub> O 80:20 v/v with 0.025 AcOH, flow rate 0.5 mL/min, detection UV 280 nm; (A) capsinoid analogue 4 and 5 (B) capsinoid analogue 6 and 7 ..... 57

## LIST OF FIGURES (CONT.)

Figure	Page
33	Percent remaining of capsinoid analogues (4-7) within 24 hours. The instance area were observed every 6 hours..... 58
34	%Cell viability of Caco-2 cells by using Cytotoxicity MTT assay treated with capsinoid analogues (4-7), capsaicin use as negative control, and capsiate use as positive control. The variation of dose at 0.1, 1, 10, 100, and 200 $\mu$ M, respectively with 1% PEG+DMEM vehicle for 18 hours..... 62
35	%Cell viability of Caco-2 cells by using Cytotoxicity MTT assay treated with capsinoid analogues (4-7), capsaicin use as negative control, and capsiate use as positive control. The variation of dose at 0.1, 1, 10, 100, and 200 $\mu$ M, respectively with 1% PEG+DMEM vehicle for 24 hours ..... 63
36	IC50 value plot between %Cell viability of control and Log concentration of each analogue (4-7) ..... 64
37	$^1\text{H}$ NMR Spectrum of (4-carboxybutyl)triphenylphosphonium bromide (9)(D <sub>2</sub> O)..... 73
38	$^1\text{H}$ NMR Spectrum of (Z)-7-methyl-5-octenoic acid (10) (CDCl <sub>3</sub> ) ..... 73
39	$^1\text{H}$ NMR Spectrum of (E/Z)-7-methyl-5-octenoic acid (11, 10) (CDCl <sub>3</sub> ) ..... 74
40	$^1\text{H}$ NMR Spectrum of (E/Z)-7-methyl-5-octenol (12, 13) (CDCl <sub>3</sub> )..... 74
41	Overlay FT-IR spectrum of mixture (E/Z)-7-methyl-5-octenoic acid (11 and 10) and (E/Z)-7-Methyl-5-octenol (12 and 13) ..... 75
42	$^1\text{H}$ NMR Spectrum of capsinoid analogue 4 (CDCl <sub>3</sub> )..... 75
43	FT-IR spectrum of mixture capsinoid analogue 4 and 5..... 76
44	$^{13}\text{C}$ NMR Spectrum of capsinoid analogue 4 (CDCl <sub>3</sub> ) ..... 76
45	$^1\text{H}$ NMR Spectrum of (E)-8-methyl-6-nonenol (17) and 8-methylnonanol (18) (CDCl <sub>3</sub> )..... 77

## LIST OF FIGURES (CONT.)

Figure	Page
46	Overlay FT-IR spectrum of mixture (E)-8-methyl-6-nonenol (17) and 8-methylnonanol (18) ..... 77
47	<sup>1</sup> H NMR Spectrum the mixture of capsinoid analogue 6 and 7 (CDCl <sub>3</sub> ) ..... 78
48	FT-IR spectrum of mixture capsinoid analogue 6 and 7..... 78
49	Chromatogram of capsinoid analogues (4-7) at 0 hour, C18, 4.6 x 250 mm, 5 μm, mobile phase, CH <sub>3</sub> OH:H <sub>2</sub> O 80:20 v/v with 0.025 AcOH, flow rate 0.5 mL/min, detection UV 280 nm ..... 79

## LIST OF SCHEMES

Scheme	Page
1	Biosynthesis pathway of capsaicin and capsiate ..... 9
2	Structures of the decomposition products from vanillyl nonanoate in methanol and ethanol were determined to methyl and ethyl vanillyl ethers..... 12
3	Enzymatic synthesis of capsinoids with immobilized enzyme, Novozym 435 ..... 22
4	Synthesis of capsiate and acetyl-capsiate <i>via</i> acetylation..... 23
5	Synthesis diagram of ( <i>E/Z</i> )-7-methyl-5-octenol ( <b>12-13</b> )..... 24
6	Synthesis diagram of capsinoid analogue <b>4</b> and <b>5</b> ..... 25
7	Synthesis of ( <i>E</i> )-8-methyl-6-nonenol ( <b>17</b> ) and 8-methylnonanol ( <b>18</b> ) <i>via</i> reduction ..... 25
8	Synthesis diagram of capsinoid analogue <b>6</b> and <b>7</b> ..... 26
9	Synthesis of (4-carboxybutyl)triphenylphosphonium bromide ( <b>9</b> ) ..... 29
10	Synthesis of ( <i>Z</i> )-7-methyl-5-octenoic acid ( <b>10</b> ) <i>via</i> Wittig reaction ..... 30
11	Synthesis of ( <i>E</i> )-7-methyl-5-octenoic acid ( <b>11</b> ) ..... 30
12	Synthesis of ( <i>E/Z</i> )-7-methyl-5-octenol ( <b>12-13</b> ) <i>via</i> reduction ..... 31
13	Synthesis of capsinoid analogue <b>4</b> and <b>5</b> <i>via</i> esterification ..... 32
14	Synthesis of ( <i>E</i> )-8-methyl-6-nonenol ( <b>17</b> ) and 8-methylnonanol ( <b>18</b> ) <i>via</i> reduction ..... 34
15	Synthesis of capsinoid analogue <b>6</b> and <b>7</b> <i>via</i> esterification ..... 35
16	Equilibrium state of quinonemethide, degradation byproduct from capsinoids ..... 39
17	The overview synthesis of capsinoid analogue <b>4</b> and <b>5</b> ..... 41

## LIST OF SCHEMES (CONT.)

Scheme		Page
18	Degradation mechanism of conventional capsinoids in protic solvent .....	59
19	Proposed stability of inverse ester position in capsinoid analogues in protic solvent compared with conventional <i>E</i> -capsiate .....	60
20	Mechanism of MTT inside active mitochondria .....	61
21	S <sub>N</sub> 2 mechanism of 5-bromovaleric acid ( <b>8</b> ) <i>via</i> triphenylphosphine .....	80
22	Wittig reaction mechanism of phosphine ylide with isobutyraldehyde producing ( <i>Z</i> )-7-methyloct-5-enoic acid ( <b>10</b> ) .....	80
23	Generation of nitrosonium cation from sodium nitrite and nitric acid .....	81
24	Isomerization of ( <i>Z</i> )-7-methyloct-5-enoic acid ( <b>10</b> ) to ( <i>E</i> )-7-methyloct-5- enoic acid ( <b>11</b> ) <i>via</i> nitrosonium cation .....	81
25	Reduction mechanism of ( <i>E</i> )-7-methyl-5-octenoic acid ( <b>11</b> ) to ( <i>E</i> )-7-Methyl-5-octenol ( <b>12</b> ) <i>via</i> LiAlH <sub>4</sub> as a reducing agent .....	81
26	Esterification reaction mechanism <i>via</i> DCC, DMAP and HOBt as a coupling agent.....	82
27	Reduction mechanism of the mixture compounds ( <b>15</b> , <b>16</b> ) to ( <i>E</i> )-8 Methyl-6-nonenol ( <b>17</b> ) and 8-methylnonanol ( <b>18</b> ) <i>via</i> LiAlH <sub>4</sub> as a reducing agent .....	83
28	Esterification reaction mechanism of 6, 7 <i>via</i> DCC, DMAP and HOBt as a coupling agent .....	84

## LIST OF ABBREVIATIONS

$\delta$	=	chemical shift
$\mu\text{M}$	=	micromolar
AR	=	analytical reagent
BAT	=	brown adipose tissue
BMI	=	body mass index
$\text{CDCl}_3$	=	deuterated chloroform
$\text{CH}_2\text{Cl}_2$	=	dichloromethane
$\text{CHCl}_3$	=	chloroform
<i>d</i>	=	doublet
$\text{D}_2\text{O}$	=	deuterium oxide
DCC	=	<i>N,N'</i> -dicyclohexylcarbodiimide
DMAP	=	4-dimethylaminopyridine
DMEM	=	dulbecco's modified eagle's medium
DMF	=	<i>N,N'</i> -dimethylformamide
DMSO	=	dimethylsulfoxide
$\text{DMSO-}d_6$	=	deuterated dimethylsulfoxide
EtOAc	=	ethyl acetate
FBS	=	fetal bovine serum
FDA	=	food and drug administration
FT-IR	=	fourier transform infrared spectroscopy
g	=	gram(s)
HOBt	=	1-hydroxybenzotriazole
HPLC	=	high performance liquid chromatography
<i>J</i>	=	coupling constant
$\text{LiAlH}_4$	=	lithium aluminium hydride
<i>m</i>	=	multiplet
<i>m/z</i>	=	mass-to-charge ratio
Me	=	methyl
MeOH	=	methanol

## LIST OF ABBREVIATIONS (CONT.)

mg	=	milligram(s)
MHz	=	megahertz
min	=	minute
mL	=	milliliter(s)
mm	=	millimeter(s)
mM	=	millimolar
mmol	=	millimole
MS	=	mass spectrometry
MTT	=	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
nm	=	nanometer
nM	=	nanomolar
NMR	=	nuclear magnetic resonance
<i>p</i>	=	para
pAMT	=	putative aminotransferase
PBS	=	phosphate buffered saline
ppm	=	part per million
$R_f$	=	retention factor
RMR	=	resting metabolic rate
RTX	=	resiniferatoxin
<i>s</i>	=	singlet
SNS	=	sympathetic nervous system
<i>t</i>	=	triplet
THF	=	tetrahydrofuran
TMS	=	tetramethylsilane
<i>t</i> -Bu	=	<i>tertiary</i> -butyl
THF	=	tetrahydrofuran
TLC	=	thin layer chromatography
TPP	=	triphenylphosphine
TRPV1	=	transient receptor potential cation channel subfamily V member 1

## **LIST OF ABBREVIATIONS (CONT.)**

UCP-1	=	uncoupling protein 1
UCP-2	=	uncoupling protein 2
UCP-3	=	uncoupling protein 3
UV	=	ultraviolet
v/v	=	Volume by volume
w/w	=	weight by weight
WAT	=	white adipose tissue